These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1176 related items for PubMed ID: 12606523

  • 1. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [Abstract] [Full Text] [Related]

  • 2. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
    Chan DC, Watts GF, Ooi EM, Ji J, Johnson AG, Barrett PH.
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1831-7. PubMed ID: 18566295
    [Abstract] [Full Text] [Related]

  • 3. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M, Egger P, Soudant C, Le Goff W, van Tol A, Dupuis R, Chapman MJ.
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [Abstract] [Full Text] [Related]

  • 4. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
    Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA.
    Diabetes; 2002 Aug; 51(8):2377-86. PubMed ID: 12145148
    [Abstract] [Full Text] [Related]

  • 5. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D, Griglio S, Le Naour G, Chapman MJ.
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [Abstract] [Full Text] [Related]

  • 6. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG.
    J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
    [Abstract] [Full Text] [Related]

  • 7. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
    Millar JS, Brousseau ME, Diffenderfer MR, Barrett PH, Welty FK, Faruqi A, Wolfe ML, Nartsupha C, Digenio AG, Mancuso JP, Dolnikowski GG, Schaefer EJ, Rader DJ.
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1350-6. PubMed ID: 16574893
    [Abstract] [Full Text] [Related]

  • 8. Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome.
    Ooi EM, Ng TW, Watts GF, Chan DC, Barrett PH.
    J Lipid Res; 2012 Nov; 53(11):2443-9. PubMed ID: 22930812
    [Abstract] [Full Text] [Related]

  • 9. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK, Lichtenstein AH, Barrett PH, Dolnikowski GG, Schaefer EJ.
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [Abstract] [Full Text] [Related]

  • 10. Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.
    Bilz S, Wagner S, Schmitz M, Bedynek A, Keller U, Demant T.
    J Lipid Res; 2004 Jan; 45(1):174-85. PubMed ID: 14523053
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH.
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1568-76. PubMed ID: 21816786
    [Abstract] [Full Text] [Related]

  • 12. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [Abstract] [Full Text] [Related]

  • 13. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [Abstract] [Full Text] [Related]

  • 14. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC, Lamarche B, Deshaies Y, Tremblay AJ, Bergeron J, Gagné C, Couture P.
    Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
    [Abstract] [Full Text] [Related]

  • 15. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
    Zulewski H, Ninnis R, Miserez AR, Baumstark MW, Keller U.
    J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
    [Abstract] [Full Text] [Related]

  • 16. Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.
    Chan DC, Watts GF, Ooi EM, Rye KA, Ji J, Johnson AG, Barrett PH.
    Diabetes Care; 2009 Nov; 32(11):2111-3. PubMed ID: 19651918
    [Abstract] [Full Text] [Related]

  • 17. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ, Otto C, Geiss HC, Schwandt P, Parhofer KG.
    Am J Cardiol; 2001 Jan 01; 87(1):44-8. PubMed ID: 11137832
    [Abstract] [Full Text] [Related]

  • 18. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ.
    Atherosclerosis; 2002 Sep 01; 164(1):129-45. PubMed ID: 12119202
    [Abstract] [Full Text] [Related]

  • 19. Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.
    Watts GF, Ji J, Chan DC, Ooi EM, Johnson AG, Rye KA, Barrett PH.
    Clin Sci (Lond); 2006 Sep 01; 111(3):193-9. PubMed ID: 16700661
    [Abstract] [Full Text] [Related]

  • 20. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
    Aguilar-Salinas CA, Barrett PH, Kelber J, Delmez J, Schonfeld G.
    J Lipid Res; 1995 Jan 01; 36(1):188-99. PubMed ID: 7706943
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.